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Abstract 20 
Background: Allergen-specific immunotherapy has been anticipated to be a 21 
disease-modifying therapy for food allergies. We previously reported that CD8
+
 22 
regulatory T cells may prevent antigen-sensitized mice from developing allergic 23 
diarrhea. Because oligomannose-coated liposomes (OML) have been shown to induce 24 
MHC class I-restricted CD8
+
 T cell responses, we analyzed the adjuvant activities of 25 
OML for inducing regulatory CD8
+
 T cells and mucosal tolerogenic responses in 26 
allergen-sensitized mice.  27 
Methods: BALB/c mice that were previously sensitized to ovalbumin (OVA) were 28 
intranasally immunized with OVA-encased in OML (OVA-OML) or OVA-encased in 29 
non-coated liposomes (OVA-NL). We assessed allergic diarrhea induced by oral OVA 30 
administration, OVA-specific immunoglobulin production, and cytokine production in 31 
the intestines and mesenteric lymph nodes (MLNs).  32 
Results: Intranasal immunization with OVA-OML, but not OVA-NL, suppressed the 33 
development of allergic diarrhea. This was associated with in vitro Ag-induced IL-10 34 
production and the in vivo expansion of CD8
+
CD28
-
 and CD4
+
CD25
+
Foxp3
+
 T cell 35 
populations among mesenteric lymph node mononuclear cells, and was significantly 36 
ablated by anti-SIGNR1 or anti-CR3 mAbs. Up-regulation of serum OVA-specific IgE 37 
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was suppressed, whereas OVA-specific IgG1, IgG2a, and soluble IgA production were 38 
enhanced by intranasal administration of OVA-OML. Adoptive transfer of CD8
+
CD28
-
 39 
T cells but not CD8
+
CD28
+
 T cells from the MLNs of OVA-OML-treated mice 40 
ameliorated the development of diarrhea.  41 
Conclusion: These results suggest that intranasal immunization with Ag-encased OML 42 
may be an effective immunotherapy for food allergies, as it induces a subset of 43 
regulatory CD8
+
 T cells as well as CD4
+
CD25
+
Foxp3
+
 T cell and modulates humoral 44 
immune responses in allergen-sensitized mice. 45 
 46 
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Introduction 52 
Food allergy is often associated with aberrant Th2-type immune responses and the 53 
breakdown of oral tolerance to food antigens (Ags). Recently, a number of 54 
immunotherapeutic approaches have been reported that focused on the induction of oral 55 
tolerance (1, 2).  Classical allergen-specific immunotherapy for food allergy by 56 
delivering Ag via the subcutaneous route can result in severe adverse reactions. Thus, 57 
appropriate Ag delivery routes and systems are needed to improve Ag targeting to the 58 
mucosal immune system.  59 
The reduction of food allergy symptoms by immunotherapy or by outgrowing them 60 
has been hypothesized to be mediated by the induction of regulatory T cells, as well as 61 
by a shift from a Th2 to a Th1 response, and/or by the balance between allergen-specific 62 
IgE and IgG antibodies, which may regulate mast cell and basophil activities (3, 4). We 63 
recently demonstrated that inducible CD8
+
 T cells may prevent Ag-sensitized mice from 64 
developing allergic diarrhea (5). Thus, manipulating CD8
+
 regulatory T cells is 65 
anticipated to be a novel therapeutic strategy for food allergy.  66 
Presentation of exogenous Ags on MHC class I molecules, termed cross-presentation, 67 
is essential for the induction of CD8
+
 T-cell responses (6-8). Several studies have 68 
demonstrated that Ag mannosylation or mannosylated Ag delivery systems, such as 69 
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mannosylated-liposomes, could enhance not only MHC class II-, but also MHC class 70 
I-restricted Ag presentation and T cell stimulation by targeting mannose receptors on 71 
APCs (9, 10). Recently, oral delivery of highly manonnosylated Ag has been shown to 72 
selectively target dendritic cells in the lamina propria via specific ICAM-3 grabbing 73 
non-integrin-related 1 (SIGNR1) and, thereby, induce the generation of CD4
+
 type 1 74 
regulatory T (Tr1)-like cells that expressed IL-10 and interferon- (11). However, 75 
incorporating new glycosylation sites by genetic engineering or by direct attachment of 76 
mannose residues to non-glycosylated Ags may compromise their inherent 77 
immunogenicity.  78 
Kojima et al. (12) reported that liposomes coated with synthetic neo-glycolipids 79 
comprised of mannotriose and dipalmitoylphosphatidylcholine (oligomannose-coated 80 
liposomes; OML) induced a Th1-like immune response with cytotoxic T cells specific 81 
for Ags encased in the liposomes following subcutaneous or intraperitoneal 82 
administration (12, 13). Intranasal delivery of OML was shown to induce both mucosal 83 
and systemic immune responses (14). SIGNR1 acts as a receptor for the recognition of 84 
OML (15). These results led us to hypothesize that OML could be used as a mucosal 85 
adjuvant to induce regulatory CD8
+
 T cells, Tr1-type immunity, and mucosal immune 86 
responses.  87 
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The aim of this study was to determine whether intranasal administration of OML 88 
could induce mucosal tolerogenic responses in mice that had been previously sensitized 89 
to OVA, a model food Ag. Our results indicate that intranasal administration of OML 90 
induces regulatory CD8
+
 T cells and Ag-specific secretory IgA in localized tissues of 91 
OVA-sensitized mice and, thereby, ameliorates the development of allergic diarrhea.92 
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Materials and methods 93 
Food allergy animal models 94 
BALB/c mice were bred under standard pathogen-free conditions. All animal 95 
experiments were performed in accordance with institutional guidelines as approved by 96 
the Animal Care Review Board of the University of Fukui. Six-week-old female mice 97 
were sensitized to OVA or ovomucoid (OM) (Sigma-Aldrich Co., St. Louis, MO) by 98 
intraperitoneal injection of 100 g of OVA or OM in alum (Imject Alum, Thermo 99 
Scientific, Rockford, IL) on days -35 and -21. Beginning on day 0, the sensitized mice 100 
received challenges by oral gavage of 20 mg OVA or OM dissolved in 0.2 ml PBS every 101 
other day for up to 6 doses. Before each intragastric challenge, mice were deprived of 102 
food for 2 hours. Diarrhea was assessed visually and body temperature was monitored 103 
for up to 1 hour following intragastric challenge.  104 
 105 
OVA-OML and treatments 106 
OVA-encased in oligomannose-coated liposomes (OVA-OML) and control 107 
OVA-encased in non-coated naked liposomes (OVA-NL) were purchased from Bio Med 108 
Core Inc. (Yokohama, Japan). The OML were comprised of 109 
dipalmitoylphosphatidylcholine : cholesterol: 110 
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mannotriose-dipalmitoylphosphatidylethanolamine (10:10:1) with a particle size of 1 111 
m (13). OVA-OML, OVA-NL, or OVA PBS solution (20 l/dose each), containing 0.2 112 
g OVA/dose, was administrated into the left side of the nose of sensitized mice by 113 
intranasal instillation over 5 minutes for up to 5 doses from days -14 to -10. 114 
Anti-SIGNR1 mAb (ER-TR9) (AbD Serotec, Oxford, UK), or anti-complement 115 
receptor 3 (CR3) mAb (M1/70) (AbD Serotec), or control rat Ig (2g/dose) was 116 
intranasally administrated 5 minutes before each intranasal instillation of OVA-OML. 117 
 118 
Adoptive transfer of primed CD8
+
 T cells 119 
Total CD8
+
 T cells, and CD28
+
 and CD28
-
 CD8
+
 T cell subsets were purified from 120 
mesenteric lymph nodes (MLNs) of OVA-sensitized and challenged mice using MACS 121 
CD8
+
 T cell Isolation Kits (Milteni Biotec GmbH, Bergish Gladbach, Germany) and a 122 
FACSCanto II (BD Biosciences). A total of 0.8 x 10
6
 CD8
+
 T cells, CD28
+
CD8
+
 T cells, 123 
or CD28
-
CD8
+
 T cells per mouse were adoptively transferred into OVA-sensitized mice 124 
by intravenous injection on day -1. 125 
 126 
Monoclonal antibodies and flowcytometry 127 
Anti-mouse CD3, CD4, CD8, CD25, CD28, CD103, CD122, and CTLA-4 mAbs 128 
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were purchased from BD Biosciences. Cells were stained using standard procedures and 129 
analyzed with a FACSCalibur (BD Biosciences).  130 
 131 
Cell culture 132 
Twenty-four hours after the last OVA challenge, mononuclear cells from MLNs were 133 
isolated.  Cells (1 x 10
5
/well) were cultured either with medium alone (RPMI 1640 134 
supplemented with 50 mM HEPES, 100 U/ml penicillin, 100 g/ml streptomycin, 2 x 135 
10
-5
 M 2-mercaptoethanol, and 10% heat inactivated fetal calf serum (Sigma-Aldrich 136 
Co.) or with OVA (1 mg/ml) for 72 h. Supernatants were collected for cytokine 137 
measurements.  138 
 139 
Cytokine and OVA-specific antibody measurements 140 
IL-4, IL-10, and IFN- in the culture supernatants were measured by a two-site 141 
sandwich ELISA, as described previously (5). Serum levels of OVA-specific IgG1, 142 
IgG2a, and IgE and the concentration of OVA-specific secretory IgA in intestinal lavage 143 
fluids, obtained by washing 10 cm of intestine with 1 ml of PBS, were determined by 144 
ELISAs, as described previously (5).  145 
 146 
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Real-time polymerase chain reaction 147 
Total RNA was isolated from samples of the jejunum and mRNA levels were 148 
quantified as described previously (5).  Results were expressed as relative units, which 149 
were calculated by the comparative Ct method.  150 
 151 
Statistical analysis 152 
Results are given as means ± standard errors of the mean. Comparisons of 2 groups 153 
used unpaired Student’s t-tests, unless an F-test showed that the variances were 154 
significantly different. When variances were significantly different, Welch’s test was 155 
used. Comparisons of the occurrences of diarrhea were made by Kaplan-Meier survival 156 
analysis. A p-value < 0.05 was considered statistically significant. 157 
158 
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Results 159 
Nasal immunization with OVA-OML alleviates allergic diarrhea 160 
As previously described (5, 16, 17),
 
the OVA- and OM-sensitized mice developed 161 
allergic diarrhea accompanied by hypothermia after repetitive intragastric OVA and OM 162 
challenges, respectively (Fig. 1B and 1C). Intranasal instillation of OVA-OML inhibited 163 
the development of allergic diarrhea and hypothermia in OVA-sensitized and challenged 164 
mice, but not in OM-sensitized and challenged mice, indicating that the effects of 165 
immunotherapy with OML is Ag-specific.  166 
In the jejunum of OVA-sensitized mice, intragastric OVA challenges increased the 167 
infiltration of eosinophils and the mRNA expression of IL-4, IFN-, IL-10, and TGF- 168 
with a Th2 dominant pattern and increased mucosal mast cell protease-1 (mmcp1) 169 
mRNA expression (Fig. 1D - F). Immunotherapy with intranasal instillation of 170 
OVA-OML significantly suppressed the accumulation of eosinophils and the mRNA 171 
up-regulations of mmcp1 and IL-4, while it marginally reduced the mRNA expression 172 
of IFN-, IL-10, and TGF1.  173 
 174 
Oligomannose residues are essential for the adjuvant effects of OML. 175 
We next asked whether the oligomannose residues on liposomes were critical for the 176 
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suppressive effects of intranasal instillation of OVA-OML. OVA-sensitized mice were 177 
intranasally immunized with OVA entrapped in carbohydrate-uncoated, bare liposomes 178 
(OVA-NL) or OVA alone. Intranasal instillation of OVA-NL or OVA alone did not 179 
inhibit the development of allergic symptoms, the accumulation of eosinophils, and the 180 
increases in IL-4 and mmcp1 mRNA expression in the jejunum (Fig. 2).   181 
 182 
Intranasal immunization with OVA-OML modulates Ag-specific immunoglobulin 183 
production. 184 
Before OVA challenges there were no significant differences in the serum levels of 185 
OVA-specific IgE, IgG1 and IgG2a Abs between OVA-OML-treated mice and untreated 186 
mice (Fig. 3). After repetitive challenges, the serum OVA-specific IgE levels of 187 
OVA-OML-treated mice were lower than those of untreated mice, whereas the serum 188 
levels of OVA-specific IgG1 and IgG2a and the concentration of secretory 189 
OVA-specific IgA in the intestinal lavage fluids of OVA-OML-treated mice were higher 190 
than those of untreated mice.  191 
 192 
OVA-OML treatment modifies the phenotype and function of MLN cells 193 
Because MLNs play critical roles in the development of food allergy and oral 194 
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tolerance (17, 18), we analyzed in vitro OVA-induced cytokine production by MNL 195 
mononuclear cells purified from the mice after repetitive OVA challenges. Intranasal 196 
immunization with OVA-OML significantly increased the in vitro OVA-induced IL-10 197 
production by MLN mononuclear cells, but did not significantly affect OVA-induced 198 
IL-4 and IFN- production (Fig. 4A). 199 
To assess the expansion of regulatory T cell populations in MLNs after intranasal 200 
immunization with OVA-OML, we analyzed MLN T cell subsets. As shown in Fig 4B, 201 
the frequencies of CD4
+
Foxp3
+
 T cells, and CD8
+
CD28
-
 T cells, but not that of 202 
CD8
+
CD122
+
T cells, or CD8
+
CD103
+
T cells among MLN T cells significantly 203 
increased in the intranasally-immunized mice compared with non-immunized mice.  204 
 205 
Adoptive transfer of MLN CD8
+
 T cells alleviates allergic diarrhea. 206 
To determine whether the MLN CD8
+
 T cells functioned as regulatory T cells in vivo 207 
to inhibit the development of allergic diarrhea, mononuclear cells or CD8
+
 T cells that 208 
were purified from OVA-OML-treated or untreated mice after repetitive OVA 209 
challenges were adoptively transferred to other OVA-sensitized mice. As shown in Fig 5, 210 
adoptive transfer of CD8
+
 T cells from OVA-OML-treated mice, but not from untreated 211 
mice, significantly inhibited the development of diarrhea and hypothermia. These cells 212 
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also abrogated the up-regulation of mmcp1 and IL-4 mRNA expression in the intestine, 213 
although to a lesser extent. Adoptive transfer of CD8
+
 T cells from OVA-OML treated 214 
mice slightly, but significantly, suppressed the up-regulation of serum levels of 215 
OVA-specific IgE and enhanced serum OVA-specific IgG2a levels, but did not affect 216 
OVA-specific secretory IgA levels in intestinal lavage fluids (Figure 5).  217 
To characterize the phenotype of CD8
+
 T cells with these suppressive effects, 218 
CD28
-
CD8
+
 T cells were purified from MLNs of OVA-OML-treated mice using 219 
fluorescence-activated cell sorting. CD28
-
CD8
+
 T cells were responsible for the 220 
suppressive effects on the allergic symptoms in vivo, whereas CD28
+
CD8
+
 T cells had 221 
little, if any, effect (Figure 6A-C). 222 
 223 
SINGNR1 and CR3 are necessary for the therapeutic effects of OVA-OML. 224 
Since CR3 is known to cooperatively act with SIGNR1 as a receptor for recognition 225 
and uptake of OMLs (15), we administered anti-SIGNR1 mAb or anti-CR3 mAb to 226 
OVA-sensitized mice before intranasal instillation of OVA-OML. The suppressive 227 
effects of intranasal instillation of OVA-OML were significantly ablated by 228 
anti-SIGNR1 mAb or anti-CR3 mAb (Figure 6D-F).   229 
230 
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Discussion 231 
In the present study, we examined a novel therapeutic approach for food allergy using 232 
intranasal immunization of Ag entrapped in OML. The mechanisms of intranasal 233 
immunotherapy with OML appeared to be due (1) to the induction of regulatory CD8
+
 T 234 
cells, primarily among the CD28
-
CD8
+
 T cell population, as well as CD4
+
CD25
+
Foxp3
+
 235 
T cells and (2) to the modulation of humoral immune responses, including enhanced 236 
Ag-specific IgGs and secretory IgA production and suppressed up-regulation of 237 
Ag-specific IgE. SIGNR1 and CR3 are involved in the therapeutic effects of 238 
OVA-OML. 239 
Various phenotypes of regulatory CD8
+
 T cells have been identified in different 240 
experimental systems (19, 20). In an experimental inflammatory bowel disease model, 241 
naturally occurring CD8
+
CD28
-
CD122
-
 regulatory T cells inhibited IFN- production by 242 
colitogenic CD4
+ 
T cells and prevented colitis. (21). Intraperitoneal application of 243 
zwitterionic capsular polysaccharides of commensal bacteria increased CD8
+
CD28
-
 T 244 
cells, which exhibited immunosuppressive properties on CD4
+
 T cells (22). The 245 
expanded CD8
+
CD28
-
 T cell population found in the MLNs of OVA-OML immunized 246 
mice displayed a more robust regulatory function than did the CD8
+
CD28
+
 T cell 247 
population in vivo, suggesting that the therapeutic effects of OML instillation could be 248 
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attributed, in part, to the induction of CD8
+
CD28
-
 regulatory T cells. 249 
Treatment of peanut Ag-sensitized mice with a Chinese herbal medicine preparation 250 
(FAHF-2) prevented oral Ag-challenge-induced anaphylaxis (23). The inhibitory effect 251 
of FAHF-2 was mediated by increased IFN- production by CD8+ T cells. By 252 
comparison, we recently demonstrated that the IL-10-producing capability of CD8
+
 T 253 
cells and IL-10 expression by MLNs were associated with alleviating allergic diarrhea 254 
(5). IL-10 and TGF- play essential roles in the suppressive activities of CD8+CD28- 255 
regulatory T cells (21, 22). Takayama et al. (24) reported that IL-10-producing 256 
CD4

CD25
+
Foxp3
+
 T cells in Peyer’s patches inhibited the development of allergic 257 
diarrhea. Intranasal immunization with OVA-OML increased the percentages of 258 
CD4
+
CD25
+
Foxp3
+
 T cells and CD28
-
CD8
+
 T cells, and enhanced Ag-induced IL-10 259 
production by MLN cells in vitro. IL-10 rather than IFN- production by MLNs may be 260 
involved in the therapeutic effects of OVA-OML immunization. 261 
It is well known that the production of IgG1 and IgE is regulated by a Th2 response, 262 
whereas IgG2a production is regulated by a Th1 response (25). Immunotherapy with 263 
OVA-OML enhanced the up-regulation of both OVA-specific IG2a and IgG1, 264 
indicating no appreciable shift from Th2- to Th1-dominant humoral responses. 265 
IL-21R-/- mice exhibit impaired Ag-specific IgG1 production and augmented 266 
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Ag-specific IgE production (26). Although IL-21 was not detected in the supernatants of 267 
OVA-stimulated MLN mononuclear cells (data not shown), IL-21 might explain the 268 
discordant IgE and IgG1 responses in OVA-OML-treated mice. Schmitz et al. (27) 269 
reported that immunotherapy with recombinant cat allergen displayed on virus-like 270 
particles induced allergen-specific IgG1 production and abolished an IgE memory 271 
response in allergen-sensitized mice and that the allergen-specific IgG antibodies 272 
alleviated allergic symptoms in FcRIIb-dependent and independent manners. The 273 
enhanced OVA-specific IgG1 and IgG2a production might also account for the 274 
therapeutic effects of OVA-OML immunotherapy.       275 
Actively tolerized mice were found to have higher fecal Ag-specific IgA titers than 276 
anaphylactic mice (28). Adoptive transfer of CD8
+
 T cells from OVA-OML immunized 277 
mice failed to induce OVA-specific secretory IgA production and tended to exhibit 278 
weaker inhibitory effects on the development of food allergy than OVA-OML 279 
immunization itself (Fig. 2 and Fig. 5). Although this might have been due to the small 280 
number of transferred CD8
+
 T cells, secretory IgA may also play a protective role 281 
against the development of food allergy by preventing the uptake of food Ag with intact 282 
epitopes from mucosal surfaces.  283 
In summary, our results demonstrate that Ag entrapped in OML has potential uses for 284 
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treating established allergies and at least two different mechanisms may be involved: 285 
induction of regulatory T cells and modulation of humoral immunity. It is difficult to 286 
determine the relative contributions of CD8
+
CD28
-
 and CD4
+
CD25
+
Foxp3
+
 T cells and 287 
humoral immunity to OML-induced suppression of food allergic symptoms. Multiple 288 
mechanisms may act synergistically suppress of allergic symptoms. Because OML are 289 
comprised of innocuous materials, are ubiquitously distributed throughout the body (29), 290 
they could be useful as an immunotherapy adjuvant and Ag delivery system for food 291 
allergy. 292 
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Figure legends 391 
Figure 1. Intranasal immunization with OVA-OML ameliorates the development of 392 
allergic diarrhea. (A) Experimental protocol. (B) Diarrhea occurrence following 393 
repetitive challenges and (C) body temperature changes after the last challenge in 394 
non-immunized, OVA-sensitized mice (open circles), non-immunized, OM-sensitized 395 
mice (open squares), OVA-OML-immunized, OVA-sensitized mice (closed circles), or 396 
OVA-OML-immunized, OM-sensitized (closed squares); n = 12/group.  (D) Jejunum 397 
of negative control non-challenged, positive control non-immunized or OVA-OML 398 
immunized OVA-sensitized mice. (E) Numbers of eosinophils and (F) cytokine and 399 
mmcp1 mRNA expression in the jejunum of positive control non-immunized mice 400 
(filled bars) and OVA-OML immunized mice (hatched bars) after the last challenge. 401 
Results for non-sensitized mice (open bars) and sensitized mice (dotted bars) without 402 
challenges are negative controls. Results are means ± SE (n = 6) and are representative 403 
of 3 independent experiments. Kaplan-Meier survival analysis, unpaired Student’s 404 
t-tests, and Welch’s tests were used for statistical analysis. *p< 0.05, **p< 0.01 405 
 406 
Figure 2. Intranasal immunization with OVA-NL or OVA alone fails to suppress the 407 
development of allergic diarrhea and hypothermia. (A) Experimental protocol. (B) 408 
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Diarrhea occurrence following repetitive challenges and (C) body temperature changes 409 
after the last challenge in non-immunized mice (open circles) or in mice immunized 410 
with OVA alone (closed squares), OVA-NL (open squares), or OVA-OML (closed 411 
circles); n = 12/group.  (D) IL-4, (E) mmcp1 mRNA expression, and (F) numbers of 412 
infiltrated eosinophils in the jejunum of non-immunized mice or mice immunized with 413 
OVA alone, OVA-NL, or OVA-OML after challenges. Results for non-sensitized or 414 
sensitized mice without challenges are negative controls. Results are means ± SE (n = 6) 415 
and are representative of 3 independent experiments. Kaplan-Meier survival analysis, 416 
unpaired Student’s t-tests and Welch’s tests were used for statistical analysis. *p< 0.05, 417 
**p< 0.01 418 
 419 
Figure 3. Intranasal immunization with OVA-OML modulates Ag-specific 420 
immunoglobulin production. Serum OVA-specific (A) IgE, (B) IgG1 and (C) IgG2a 421 
concentrations of non-immunized (open circles) or OVA-OML-immunized mice (closed 422 
circles) were determined at pre-immunization, and at pre- and post-challenges. (D) 423 
OVA-specific secretory IgA in the intestinal lavage fluid was determined after 424 
challenges. Results are means ± SE (n = 6) and are representative of 3 independent 425 
experiments. Unpaired Student’s t-tests and Welch’s tests were used for statistical 426 
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analysis.  *p< 0.05 427 
 428 
Figure 4. Intranasal immunization with OVA-OML enhances OVA-induced IL-10 429 
production by MLN mononuclear cells in vitro and alters MLN T cell populations.  (A) 430 
In vitro OVA-induced IL-4, IFN- and IL-10 production by MLN mononuclear cells 431 
purified from non-immunized (open bars) and OVA-OML-immunized (filled bars) mice 432 
after challenges. Results are means ± SE (n = 6) and are representative of 3 independent 433 
experiments. Unpaired Student’s t-tests were used for statistical analysis.  *p< 0.05 (B) 434 
Results for cell surface phenotypes of MLN T cells from non-immunized and 435 
OVA-OML-immunized mice after challenges were obtained by gating on CD3
+
 cells. 436 
Indicated values are the percentages of each subset among MLN T cells. Results of one 437 
representative experiment of 6 are shown.  438 
 439 
Figure 5. Adoptive transfer of MLN CD8
+
 T cells from OVA-OML-treated mice 440 
ameliorates allergic diarrhea. (A) Experimental protocol. (B) Diarrhea occurrence 441 
following repetitive challenges and (C) body temperature change after the last challenge 442 
in non-transferred mice (open circles), mice with CD8
+
 T cells transferred from 443 
non-immunized controls (open squares), and OVA-OML immunized mice (closed 444 
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squares); n = 12/group. (D) IL-4 and (E) mmcp1 mRNA expression in the jejunum, 445 
serum OVA-specific (F) IgE, (G) IgG1, and (H) IgG2a concentrations, and (I) 446 
OVA-specific secretory IgA in the intestinal lavage fluid from non-transferred mice or 447 
from mice with MLN CD8
+
 T cells transferred from non-immunized or OVA-OML 448 
immunized mice. mRNA expression for non-sensitized and sensitized mice without 449 
challenges are negative controls. Results are means ± SE (n = 6) and are representative 450 
of 3 independent experiments. Kaplan-Meier survival analysis, unpaired Student’s 451 
t-tests, and Welch’s tests were used for statistical analysis. * p< 0.05 452 
   453 
Figure 6. Adoptive transfer of MLN CD28
-
CD8
+
 T cells but not CD28
+
CD8
+
 T cells 454 
ameliorates allergic diarrhea. (A) CD28
-
CD8
+
 T cells and CD28
+
CD8
+
 T cells were 455 
purified from MLNs mononuclear cells. (B) Diarrhea occurrence following repetitive 456 
challenges and (C) body temperature change after the last challenge in non-transferred 457 
mice (open circles), or in mice with CD28
-
CD8
+
 T cells (closed squares) or CD28
+
CD8
+
 458 
T cells (open squares) (0.8 x 10
6
/mouse) transferred from OVA-OML immunized mice; 459 
n = 8/group). (D) Experimental protocol for anti-SIGNR1 and anti-CR3 mAb treatments 460 
(E) Diarrhea occurrence following repetitive challenges and (F) body temperature 461 
change after the last challenge in non-immunized mice (open circles), or in mice 462 
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pre-treated with control Ig (closed circles), anti-SIGNR1 mAb (open squares), or 463 
anti-CD11b mAb (closed squares); n = 12/group. Kaplan-Meier survival analysis was 464 
used for statistical analysis. * p< 0.05 465 
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